VANCOUVER, British Columbia, Aug. 28, 2025 (GLOBE NEWSWIRE) — AIP Realty Trust (the “Trust” or “AIP Realty”) (TSXV:AIP.U) today announced its financial results for the three and six months ended June 30, 2025. All dollar amounts are stated in U.S. dollars. Q2 2025 HighlightsInvestment property revenue for the three ended June 30, 2025 was $150,403, compared to $152,591 in the same period in 2024, a decrease of $2,188, or 1%. The decline in investment property revenue was mainly due to a decline in parking revenue from a 2024 lease expiration that included a large parking agreement component and normal turnover that resulted in the vacancy of one unit starting in mid April 2025, partially offset by increased other revenue generated by tenant move-out charges. Investment property operating expense for the three months ended June...

Sales increased by approximately 27% compared to the same period in 2024 KFAR SABA, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, reported today its financial results for the six months ended June 30, 2025. Key Highlights of ParaZero’s Achievements in the First Half of 2025 & Recent Updates: Financial and Corporate Updates:Sales increased by 26.6% to $357,979 for the six months ended June 30, 2025. ParaZero raised approximately $3.1 million and $2.2 million in gross proceeds from registered direct offerings in February 2025 and August 2025, respectively Appointed Ariel Alon, a senior UAV executive, as company’s CEO.Counter-Drone...

SANTA CLARA, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Ambarella, Inc. (NASDAQ: AMBA), an edge AI semiconductor company, today announced financial results for its second quarter of fiscal year 2026 ended July 31, 2025.Revenue for the second quarter of fiscal 2026 was $95.5 million, up 49.9% from $63.7 million in the same period in fiscal 2025. For the six months ended July 31, 2025, revenue was $181.4 million, up 53.5% from $118.2 million for the six months ended July 31, 2024. Gross margin under U.S. generally accepted accounting principles (GAAP) for the second quarter of fiscal 2026 was 58.9%, compared with 60.8% for the same period in fiscal 2025. For the six months ended July 31, 2025, GAAP gross margin was 59.4%, compared with 60.8% for the six months ended July 31, 2024. GAAP net loss for the second quarter of fiscal 2026...

Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M – $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technology platform and growing recognition of its ability to deliver more favorable patient outcomes than legacy devices,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “Building upon our momentum in personalized lumbar fusion surgery, in July we successfully completed the first personalized cervical spine surgery using our aprevo® technology...

Record Earnings and Profitability Expansion to 10.9k GPUs & $200-250m AI Cloud Annualized Revenue by Dec 20251 GPU Financing & NVIDIA Preferred Partner Status Secured New Liquid-Cooled GB300 NVL72 Deployments NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (“IREN” or “the Company”) today reported its financial results for the full fiscal year ended June 30, 2025. HighlightsQ4 FY25 revenue of $187.3m, net income of $176.9m, Adj. EBITDA of $121.9m2, and EBITDA of $241.4m2 Approaching $1.25bn total annualized revenue with scope for further growth ahead3>$1bn annualized revenue from Bitcoin mining under current mining economics4 $200-250m annualized revenue from AI Cloud at 10.9k NVIDIA GPUs by Dec 20251Capacity to deploy >60,000 NVIDIA Blackwell GPUs across existing British Columbia data centers,...

PRESS RELEASE REGULATED INFORMATIONINSIDE INFORMATIONBrussels, 28 August 2025, 18:30 CESTBrussels, 28 August 2025 – Nextensa announces today that it has sold its entire 8.99% stake in the Belgian REIT Retail Estates. The deal was completed at a price of €66.30 per share, resulting in total proceeds of €89.6 million. This represents a substantial capital gain compared to the valuation applied in Nextensa’s half-year results published on 13 August 2025 (€61.50 per share). The transaction generates a strong inflow of cash, lowering Nextensa’s debt ratio to below 40%. This further strengthens the company’s balance sheet and financial capacity, providing additional room to invest in future development projects. This step is fully in line with Nextensa’s long-term vision: to free up capital for reinvestment in innovative and sustainable...

Nanterre, 28 August 2025 VINCI Autoroutes and VINCI Airports traffic in July 2025 I-      Change in VINCI Autoroutes’ intercity networks traffic  July YTD at the end of July (7 months)  % change 2025/2024 % change 2025/2024VINCI Autoroutes +1.0% +2.0%Light vehicles +1.0% +2.2%Heavy vehicles +0.4% +0.5%In July, light vehicle traffic increased by 1.0% and heavy vehicle traffic by 0.4%, despite one fewer working day than in July 2024. Since the beginning of the year, traffic has increased (+2.0%), both for light vehicles (+2.2%) and heavy vehicles (+0.5% despite two fewer working days than in 2024). II-      Change in VINCI Airports passenger traffic1  July YTD at the end of July(7 months)  % change 2025/2024 % change 2025/2024VINCI Airports +3.6% +5.9%Portugal (ANA) +5.2% +4.9%United Kingdom +0.3% +1.5%France +1.6% +3.8%Serbia +6.1% +5.5%Hungary +5.6% +13%Mexico...

MANAGEMENT REPORT Consolidated net sales for Q2 2025 were € 1.87 million, which was a 14% decrease compared to the same period last year (Q2 2024: € 2.18 million). The Group`s main activity is the production and wholesale of fibreboard, the sales revenue of which in Q2 2025 was € 1.87 million (Q2 2024: € 2.17 million). The remaining segment is the management of the real estate on Suur-Jõe street in Pärnu, the sales revenue of which in Q2 2025 was € 1 thousand (Q2 2024: € 9 thousand). The main difference in sales volumes between the second quarter of 2025 and the same period in 2024 is due to the decline in sales to European Union markets. Pärnu Riverside Development OÜ’s real estate management revenue on the Suur-Jõe street property decreased in Q2 2025 compared to the Q2 2024, due to the termination of rental agreements in August...

Dubai, Aug. 28, 2025 (GLOBE NEWSWIRE) — Vantage Drilling International Ltd. (“Vantage” or the “Company”) reported a net loss attributable to shareholders of approximately $16.0 million or $1.20 per diluted share for the three months ended June 30, 2025, based on the weighted average shares outstanding, as compared to a net loss attributable to shareholders of approximately $14.2 million or $1.07 per diluted share for the three months ended June 30, 2024. As of June 30, 2025, Vantage had approximately $52.9 million in cash, including $9.5 million in pre-funding for upgrading the Tungsten Explorer, $2.4 million in restricted cash and $6.9 million pre-funded by our Managed Services customers for near-term obligations. In comparison, as of December 31, 2024, Vantage had $89.6 million in cash, including $20.0 million in...

Ramat Gan, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced financial results and clinical updates for H1, 2025. Clinical & Development Milestones Achieved Namodenoson Drug Candidate – Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone The Phase 2a study (NCT06387342) is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safety (primary endpoint), clinical activity, and pharmacokinetics (PK) of Namodenoson in this patient population. Participants...